Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial

BMC Ophthalmology

Table 3 Comparison of results evaluating imiquimod treatment of periocular nodular basal cell carcinoma

First author year	N	Dosing regimen, days/week, weeks	Mean size (SD) mm	Lesions greater than 10 mm (%)	Complete response (%)	Follow-up (years)	Histological follow-up (months)
Present study	19	5/wk	11.1 (6.0)	58	84.2	3.3	36
Present study	19	8–16 wk	11.1 (6.0)	58	84.2	3.3	36
Prokosch 2011 [11]	4	5/wk	11.5 (4.5)	50	100	7.0	-
Prokosch 2011 [11]	4	6 wk	11.5 (4.5)	50	100	7.0	-
Garcia-Martin 2010 [13]	15	5/wk	7.6 (2.9)	25	100	2.0	3
Garcia-Martin 2010 [13]	15	6 wk	7.6 (2.9)	25	100	2.0	3
Carneiro 2010 [22]	10	5/wk	12.1 (6.5)	60	80	1.0	12
Carneiro 2010 [22]	10	10–16 wk	12.1 (6.5)	60	80	1.0	12
Choontanom 2007 [10]	5	5/wk	10.8 (4.2)	40	80	3.0	-
Choontanom 2007 [10]	5	6 wk	10.8 (4.2)	40	80	3.0	-
Leppälä 2007 [12]	4	5/wk	8.5 (4.6)	25	100	0.5	3
Leppälä 2007 [12]	4	6 wk	8.5 (4.6)	25	100	0.5	3
Blasi 2005 [9]	2	3/wk	-	-	100	1.0	-
Blasi 2005 [9]	2	8–12 wk	-	-	100	1.0	-

ISSN: 1471-2415